Sanofi SA · EURONEXT:SAN
Sanofi SA — Investor Day (December 2021)
21 slides from Sanofi SA's investor day presentation, Dec 1, 2021
Slide 1: Vaccines Investor Event: Epidemiology
Vaccines Investor Event Epidemiology December 1st, 2021 Getty Images
Slide 2: Agenda
Agenda Influenza RSV Pneumococcal Meningitis PPH & Boosters Chlamydia Acne 1
Slide 3: Influenza | Targeted population and current usage
Influenza | Targeted population and current usage 2020 population (m) and current usage(1) Children Adults Elderly (6 months - 17 yo) (18 - 64 yo) ≥ 65 yo U.S. 71m • Mostly SD 201m • Mostly SD 55m • Mostly HD EU 5 • DE(2): mostly HD 58m • Mostly SD 197m • Mostly SD 68m • Other: mostly SD RoW 2.1bn •
Slide 4: Influenza | Current vaccine coverage rate
Influenza | Current vaccine coverage rate % 2020 population(1) Children Adults Elderly (6 months - 17 yo) (18 - 64 yo) (65+) (2) U.S. 59% 43% 75% EU 5 (4) (4) (3) • DE: 39% • IT: 55% 16% 22% 57% • FR: 60% • SP: 66% • UK: 72% (4) (4) (4) RoW 4% 9% 18% yo: Years old EU 5: France, Germany, Italy, Spain
Slide 5: Agenda
Agenda Influenza RSV Pneumococcal Meningitis PPH & Boosters Chlamydia Acne
Slide 6: RSV | Target population and recommendation
RSV | Target population and recommendation 2020 birth cohort (m), recommendation and usage across age groups Infants Toddlers Elderly Birth cohort (0 - 11 months) (12 - 24 months) ≥ 65 yo U.S. • Palivizumab: infants <29 4m(1) - - wGA and CHD/CLD EU 5 • Palivizumab: infants <35 wGA, born <6 months 3m
Slide 7: Agenda
Agenda Influenza RSV Pneumococcal Meningitis PPH & Boosters Chlamydia Acne 6
Slide 8: PCV | Target population, recommendation and usage
PCV | Target population, recommendation and usage 2020 birth cohort (m), recommendation and usage across age groups Birth Infants Toddlers Elderly cohort (0 - 11 months) (12 - 24 months) ≥ 65 yo U.S. • PCV20 or PCV15 + • PCV13 • PCV13 4m(1) PPSV23 • 3 doses • 1 dose • 1 dose EU 5 • PCV13 reco: Italy
Slide 9: PCV | Current vaccine coverage rate
PCV | Current vaccine coverage rate % 2020 population(1) Infants Toddlers Elderly (0 - 11 months) (12 - 24 months) ≥ 65 yo U.S.(2) 98% 82% 70% EU 5(2) 95% 90% 20% RoW(3) 49% 49% 5% yo: Years old EU 5: France, Germany, Italy, Spain, United Kingdom m: Million (1) Average for total population in infant
Slide 10: Agenda
Agenda Influenza RSV Pneumococcal Meningitis PPH & Boosters Chlamydia Acne 9
Slide 11: MenC & ACWYcj | Target population, recommendation and usage
MenC & ACWYcj | Target population, recommendation and usage 2020 birth cohort (m), recommendation and usage across age groups Infants & Toddlers Adolescents Birth cohort (0 - 23 months) (11 - 17 yo) U.S. • MenACWY 4m(1) • Very limited usage • 2 doses in most states at ~11 yo, ~16 yo EU 5 • Mainly Me
Slide 12: MenC & ACWYcj | Current vaccine coverage rate
MenC & ACWYcj | Current vaccine coverage rate % 2020 population(1) Infants & Toddlers Adolescents (0 - 23 months) (11 - 18 yo) U.S. • 89% ≥1 dose coverage(2) 0% • 54% ≥2 doses coverage(2) EU 5 17% 46% RoW(3) 4% 8% yo: Years old EU 5: France, Germany, Italy, Spain, United Kingdom (1) VCR: (N*doses/sc
Slide 13: MenB | Target population, recommendation and usage
MenB | Target population, recommendation and usage 2020 birth cohort (m), recommendation and usage across age groups Infants & Toddlers Adolescents Birth cohort (0 - 23 months) (11 - 18 yo) U.S. • MenB 4m(1) • No recommendation • 2 doses at ~16yo, ~18yo(7) EU 5 • Recommendation: Italy, UK, Spain(5)
Slide 14: MenB | Current vaccine coverage rate
MenB | Current vaccine coverage rate % 2020 population(1) Infants & Toddlers Adolescents (0 - 23 months) (11 - 18 yo) U.S. 0% 28%(2) EU 5 53% 3% RoW(3) 1% 0% yo: Years old EU 5: France, Germany, Italy, Spain, United Kingdom (1) VCR = (N*doses/schedule)/cohort: EU 5/RoW infant/toddlers: country speci
Slide 15: Agenda
Agenda Influenza RSV Pneumococcal Meningitis PPH & Boosters Chlamydia Acne 14
Slide 16: PPH & Boosters | Target population, recommendation and usage
PPH & Boosters | Target population, recommendation and usage 2020 birth cohort (m), recommendation and usage across age groups Primary series Booster Booster Booster Birth cohort Infant & Toddler Child(1) Adolescent(1) Booster Adult(1) (6 weeks – 18 months) (4 - 6 yo) (10 - 18 yo) Pregnant woman(1)
Slide 17: PPH & Boosters | Current vaccine coverage rate
PPH & Boosters | Current vaccine coverage rate % 2020 population Primary series Booster Booster Booster Infant & Toddler Child(1) Adolescent(1) Booster Adult(1) (6 weeks – 18 months) (4 - 6 yo) (10 - 18 yo) Pregnant women(1) (19+ yo) U.S. (2) (2) (2) 93% >90% 90% 54% 31% (3) (3) (3) EU 5 95% >90% 76
Slide 18: Agenda
Agenda Influenza RSV Pneumococcal Meningitis PPH & Boosters Chlamydia Acne 17
Slide 19: Chlamydia | Targeted population and expected recommendation
Chlamydia | Targeted population and expected recommendation 2020 birth cohort (m) Female birth cohort U.S. 2.0m EU 5 Recommendation expected to be one single 1.5m dose for lifetime protection RoW 62.0m High proportion of incidence among 15-24yo women(1) yo: Years old EU 5: France, Germany, Italy, Sp
Slide 20: Agenda
Agenda Influenza RSV Pneumococcal Meningitis PPH & Boosters Chlamydia Acne 19
Slide 21: Acne | Prevalence of mild and moderate-to-severe acne
Acne | Prevalence of mild and moderate-to-severe acne Prevalence of acne in 2019 for all ages (m) U.S. EU 5 China RoW All forms of acne vulgaris 9 13 43 166 231 Moderate-to-severe acne 3 5 17 67 92 yo: Years old EU 5: France, Germany, Italy, Spain, United Kingdom m: Million 20 Source: IHME. GBD Resu